KNSA

Kiniksa Pharmaceuticals International, Plc

A biopharmaceutical company that makes medicines for inflammatory diseases, including ARCALYST, the first and only FDA-approved therapy for recurrent pericarditis, a painful swelling of the sac around the heart. Kiniksa was founded in 2015 by a group of former colleagues from an earlier biotech firm who reunited to keep developing treatments for rare conditions. The name Kiniksa is an invented, distinctive-sounding corporate word with no traditional meaning.

CINS: G5269C1011 holder

Jun 28, 2024 — Reclassified as KINIKSA PHARMACEUTICALS INTL (1:1)

Ownership Activity Financials Filings

KNSA

KNSA

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Entry into a Material Definitive Agreement

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition